Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study

摘要: Abstract Background Breast cancer 1 (BRCA1) protein inactivation in sporadic ovarian carcinoma (OC) is common and low BRCA1 expression linked with platinum sensitivity. The clinical validation of as a prognostic marker OC remains unresolved. Patients methods In 251 patient samples from the NCIC CTG trial, OV.16, was determined by immunohistochemistry. Results For all patients, when score analyzed continuous variable, there no significant correlation between progression-free survival (PFS) [adjusted hazard ratio (HR) = 1.15 (0.96–1.37), P 0.12] or response rate [HR 0.89 (0.70–1.12), 0.32]. 116 patients minimal residual disease (RD), higher correlated significantly worse PFS 1.40 (1.04–1.89), 0.03]. Subgroup analysis divided RD into (BRCA1 ≤2.5) high >2.5) groups. had more favorable outcome [median 24.7 16.6 months BRCA1, respectively; HR 0.56 (0.35–0.89), 0.01]. Conclusions This study suggests that RD. Further research needed to evaluate predictive biomarker target enhance chemotherapeutic